 |
|
|
| |
FEASIBILITY OF IMPLEMENTING LONG-ACTING INJECTABLE ANTI-RETROVIRAL THERAPY TO TREAT HIV:
A SURVEY OF HEALTH PROVIDERS FROM THE 13 COUNTRIES PARTICIPATING IN THE ATLAS-2M TRIAL
|
| |
| |
IAC 2020 July 6-10 Virtual
Reported by Jules Levin
IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
Deanna Kerrigan,1 Miranda Murray,2 Tahilin Sanchez Karver,3 Andrea Mantsios,4 Nicki
Walters,5 Krischan Hudson,6 Emma Kaplan-Lewis,7 Federico Pulido,8 AC Bassa,9 David Margolis,6 Noya Galai3
1George Washington University, Washington DC, USA; 2Health Analytics & Outcomes, London, UK; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 4Public Health Innovation & Action, New York, NY, USA;
5ViiV Healthcare, London, UK; 6ViiV Healthcare, Research Triangle Park, NC, USA; 7Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA; 8HIV Unit,
Hospital 12 de Octubre, imas12, UCM, Madrid, Spain; 9Mzansi Ethical Research Centre, Middelburg, South Africa
|
| |
|
|
|
|
|
